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Summary The objective of this study was to determine if the addition of megestrol acetate (MA), a modulator of P-glycoprotein-mediated
drug resistance, to first-line cytotoxic therapy in patients with limited and advanced stage small-cell lung cancer (SCLC) would improve
median time to disease progression and median overall survival. Secondary outcomes evaluated were response rates and patient symptom
profile. Between 1992 and 1995, 130 eligible patients were randomized in a double-blind fashion to receive standard first-line therapy
consisting of alternating courses of cyclophosphamide/doxorubicin/vincristine and etoposide/cisplatin (and thoracic radiotherapy for limited
stage patients), along with either placebo or MA 160 mg t.i.d. for 8 days commencing 3 days before initiation of each cycle of chemotherapy.
Treatment was continued for a maximum of six cycles. A total of 130 eligible patients were randomized, 65 to each arm. Fifty-two per cent of
patients had limited disease and 48% had advanced disease. The median time to disease progression in limited stage disease was 46 weeks
in the placebo arm and 43 weeks in the MA arm (P = 0.71) and in advanced stage disease was 28 weeks in the placebo arm and 27 weeks
in the MA arm (P= 0.92). The median overall survival in limited stage disease was 75 weeks in the placebo arm and 75 weeks in the MA arm
(P= 0.56) and in advanced stage disease was 41 weeks in the placebo arm and 39 weeks in the MA arm (P= 0.96). There was no consistent
statistical difference in response rates or patient symptom profiles between the two treatment arms. The addition of MA, in the dose and
schedule used, to standard first-line cytotoxic therapy in SCLC did not result in a significant improvement in response rates, symptom profile,
median time to disease progression or overall survival.
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Small-cell lung cancer (SCLC) represents approximately 25% of
all bronchogenic carcinoma and, untreated, has a median survival
of 12 weeks in limited-stage disease and 5 weeks in advanced-
stage disease. Cytotoxic chemotherapy has been shown to produce
high initial overall response rates of 75-95% with corresponding
improvements in median survival of 12-16 months in limited-
stage disease and 7-11 months in advanced-stage disease.
However, almost inevitably, the disease relapses and ultimately
becomes resistant to further chemotherapy (Ihde et al, 1993, page
723). Resistance to cytotoxic chemotherapy of at least one clone
at diagnosis is thought to be the main reason for failure of
chemotherapy to maintain the initial response and failure to offer
further survival improvement. Thus, a potential strategy for
improving overall survival would be to modulate drug resistance.
There are several recognized mechanisms ofdrug resistance and
multidrug resistance (MDR) in malignancies. One mechanism of
MDR correlates with an overexpression of P-glycoprotein (P-gp),
a 170-kDa transmembrance protein encoded by the MDR1 gene,
which acts as an energy-dependent efflux pump to decrease intra-
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cellulardrug accumulation (Gottesman and Pastan, 1988; Bellamy
and Dalton, 1994).
P-gp is found in many normal human tissues, including the
liver, kidney and colon. These tissues predominantly involve cells
lining the luminal space, suggesting a physiological role as a
normal transporter for toxic, naturally occurring substances.
MDR1 gene expression and P-gp expression has also been
reported in a number of solid tumours that are generally regarded
as being resistant to primary chemotherapy, including renal
cell, colorectal, hepatocellular, adrenal, pancreatic carcinomas and
sarcomas (Fojo et al, 1987; Cordon-Cardo et al, 1990; Goldstein et
al, 1990). There are also tumours and cell lines initially sensitive
to primary chemotherapy that demonstrate undetectable or low
levels of P-gp or MDR1 mRNA but on relapse or resistance to
chemotherapy express increased levels of P-gp or MDR1 RNA.
These malignancies include leukaemias and lymphomas, breast
cancer, neuroblastomas, ovarian carcinomas, as well as SCLC
(Reeve et al, 1989; Goldstein et al, 1989; Minato et al, 1990; Chin
et al, 1993). This is consistent with the concept that malignant
cells expressing P-gp at the outset have a selective growth advan-
tage during exposure to cytotoxic drugs. P-gp expression is associ-
ated with resistance to a number of natural and semisynthetic
cytotoxic drugs in vitro including the anthracyclines, mitomycin
C, vinca alkaloids, epipodophyllotoxins and actinomycin D
(Chin et al, 1993).
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P-gp-mediated drug resistance can be modulated by a number of
chemically dissimilar drugs, including verapamil, quinine, quini-
dine, cyclosporin A andhydrophobic steroids, such as progesterone
or megestrol acetate (MA) (Wang et al, 1991; Fleming et al, 1992;
Bellamy and Dalton, 1994), thereby decreasing drug resistance.
Clinically, there are practical difficulties in the routine clinical use
ofthe majority ofthese drugs because ofsignificant toxicities. MA
is devoid of these significant side-effects. Further, MA has been
found to have beneficial effects in patients with cancer by
enhancing appetite, resulting in subjective and objective improve-
ments in weight gain and appetite (Tchekmedyian et al, 1987;
Bruera et al, 1990; Loprinzi et al, 1990).
Considering these factors, the objective ofthis prospective trial
was to determine whether treating SCLC patients with MA, a
modulator of P-gp-mediated drug resistance, in addition to stan-
dard first-line cytotoxic therapy, would improve survival by elimi-
nating multidrug resistance cells carrying the MDR phenotype.
The primary outcomes evaluated were overall survival and time to
disease progression, with secondary outcomes being response
rates and symptom profiles.
METHODS
Patients and methods
This double-blind, randomized placebo-controlled, province-wide
clinical trial involved patients with histologically or cytologically
proven limited- or advanced-stage SCLC. Inclusion criteria for
patients included age < 75 years old, ECOG performance status
(PS) < 2, normal renal and cardiac function, a normal serum
bilirubin and patient written informed consent. Measurable or
assessable disease was not arequirement as theprimary endpoints
were overall and disease-free survival. Exclusion criteria included
pregnancy, prior chemotherapy or a previous or concurrent malig-
nancy (with the exception of non-melanomatous skin cancer or
in situ cervix carcinoma). The study was carried out with ethics
committee approval.
Pretreatment evaluation included pathology review, a complete
history, physical examination, baseline laboratory studies, a base-
line PS determination and a global and mutidimensional symptom
questionnaire. Patients were staged with a chest radiography,
contrast-enhanced computerized tomography (CT) scan of the
head, thorax and upper abdomen and a radionucleotide bone scan.
Tumour P-gp levels or MDR1 expression were not measured at
the time ofpresentation, progression or relapse.
Treatment and follow-up protocol
All eligible patients were randomized to receive either megesterol
acetate (MA) or placebo. MA was given at a dose of 160mg t.i.d.
commencing 3 days before initiation ofeach cycle ofchemotherapy
for a total of 8 days in each 21-day cycle. Patients randomized to
receive placebo received visually identical tablets to MA in an iden-
tical schedule. MA (Megace) and placebo tablets were supplied by
Bristol-Myers Squibb Pharmaceutical Group. All patients received
chemotherapy consisting of 3 consecutive days of intravenous (i.v.)
cisplatin 25 mgmi-2day-1 andetoposide 100mgm-2day-I alternating
with 1 day of i.v. cyclophosphamide 1000 mg m-2, doxorubicin
50mg mi-2 and 2 mg of vincristine every 3 weeks for a total of six
cycles. Limited-stage patients also received thoracic radiotherapy of
5000 cGy maximum dose ± 5% to the clinical tumour volume
divided into 25 daily fractions over 5 weeks using 6 mV photons
commencing concurrently with the second cycle of chemotherapy,
unless they had undergone a prior lobectomy orpneumonectomy.
Before each course of chemotherapy, evaluation included a
history, physical examination, PS score, blood tests and the self-
administered symptom-profile questionnaire. Complete restaging
was performed at the completion of chemotherapy and radio-
therapy treatment, unless required beforehand for clinical reasons.
Patients were taken off study for the following reasons: failure to
respond after a minimum of two cycles of chemotherapy, disease
progression at any time during the six chemotherapy cycles, unac-
ceptable toxicity or at the patient's request. After the treatment
protocol was completed, patients were seen at 3-monthly intervals
or earlier, ifrequired clinically, and were evaluated with a history,
physical examination, blood tests, chest radiography and further
investigations if required. All toxicities were graded according to
the ECOG toxicity scale.
Evaluation of response
Median disease-free survival and overall survival were the key
parameters in assessing the efficacy of MA in modulating drug
resistance. Survival was measured from time of diagnosis and all
causes of death were included. Complete response (CR) was
defined as disappearance of all clinical and radiological evidence
of tumour for a minimum of 4 weeks after completion of
chemotherapy. Partial response (PR) consisted of a reduction of
>50% of the diameter of all measurable lesions for a minimum of
4 weeks after chemotherapy. Stable disease involved a < 50%
reduction in tumour diameter of all lesions and maintained for a
minimum of8 weeks. Progression was defined as an increase ofat
least 25% in any measurable lesion or the appearance of any new
lesions.
At baseline and before each cycle of chemotherapy, patients
were asked to complete a standardized symptom-profile question-
naire with both multidimensional and global assessments using a
visual analogue scale. Globally, thepatients were asked ifthey felt
better, the same or worse than ontheirlast visit and, ifthere was an
improvement, the importance ofthis improvement.
Statistical methods
The sample size was calculated, based on the log-rank analysis of
survival, to show a 50% improvement in survival with an alpha
error of 5% and a power of 80%. Randomization occurred by a
central computer-generated code. Statistical analyses were
performed using SAS (Statistical Application Software Institute,
Cary, NC, USA) version 6.11. Life-table analyses ofsurvival data
and disease-free survival were estimated using the Kaplan-Meier
method, and chi-squared tests were used to test differences
between proportions.
The multidimensional symptom-profile data were analysed
using the entire sample size as one method proposed by Hopwood
et al (1994). The median questionnaire scores were compared
between the two treatment arms at each chemotherapy cycle using
the median test for two samples.
RESULTS
From July 1992 through August 1995, 135 patients were enrolled.
Five were later determined to be ineligible; three for incorrect
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Table 1 Baseline characteristics
Variable Megace Placebo
n=65 n=65
No. of patients
LS 35 33
AS 30 32
Mean age years (sd)
LS 60.4 (7.3) 59.8 (7.9)
AS 60.1 (6.9) 57.7 (7.7)
All 60.3 (7.1) 58.8 (7.8)
Male sex 33 38
PS
0 22 25
1 28 28
2 15 12
LS, limited stage; AS, advanced stage; SD, standard deviation. P = NS.
histology, one for age >75 years and one for poorcardiac function.
Of the 130 eligible patients enrolled, 65 were randomized to MA
and 65 to placebo. Seven patients refused further chemotherapy
after one cycle but were still included in the analysis, and no
patients were lost to follow-up. All patients were analysed
according to their initial treatment assignment.
As shown in Table 1, there were no statistically significant differ-
ences in baseline characteristics of the two arms with respect to
stage, age, sex and PS. The number ofprotocol treatments given and
delays in treatment and/ordosereductions were similarinboth arms.
The median time to disease progression was not statistically
different in the MA and placebo arms in advanced-stage (MA, 27
weeks; placebo, 28 weeks; P = 0.92) orlimited-stage disease (MA,
43 weeks; placebo, 46 weeks; P = 0.71). Median overall survival
was not statistically different in advanced-stage (MA, 39 weeks;
placebo, 41 weeks; P = 0.96) or limited-stage disease (MA, 75
weeks; placebo, 75 weeks; P = 0.56), as shown inFigure IA and B.
There were 108 patients (83%) who were evaluable for
response. Twenty-two patients were unevaluable because of
complete surgical resection or non-identifiable macroscopic
disease in six, patient withdrawal after one cycle ofchemotherapy
in seven, death after one cycle of chemotherapy in eight and lack
of data in one. The number of unevaluable patients was similar in
each arm. There was no difference in the response rates in the MA
and placebo arms in either advanced-stage (MA: CR 25%; PR
42%, progression 33%; placebo: CR 22%, PR 44%, progression
33%) or limited-stage disease (MA: CR 69%, PR 17%, stable 3%,
progression 10%; placebo: CR 75%, PR 18%, progression 7%).
Grade 3 and 4 neutropenia was not statistically different
between the two arms. A finding that was statistically significant
was that the MA arm produced more grade 4 thrombocytopenia
(2.5%) than the placebo arm (0.3%), although no significant clin-
ical bleeding resulted from this. There were three treatment-related
deaths due to sepsis; two in the MA arm and one in the placebo
arm. Thromboembolic disease occurred more often in the MA
arm (three events) than in the placebo arm (no events), but this
did not reach statistical significance. One of these three patients
had a prior history of thromboembolic disease predating their
malignancy.
There was no consistent statistically significant difference in the
individual symptoms, the sum of all symptoms or the global
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Figure 1 Kaplan-Meier overall survival curves foradvanced-stage disease
(A) and limited-stage disease (B)
assessment between the two treatment arms. The overall compli-
ance for questionnaire completion was 79%, with a range from
71% to 91% for each course.
DISCUSSION
This is the first randomized, placebo-controlled trial using MA as
a modulator ofmultidrug resistance in a solid tumour to determine
whether its use at the time offirst-line cytotoxic therapy results in
a survival benefit or improvement in time to disease progression.
The results reveal that the addition of MA did not change the
median time to disease progression or median overall survival.
There have been other randomized clinical trials studying modula-
tors of P-gp in other tumours that support these results. Three
recent large trials studied quinidine in advanced breast cancer
(Wishart et al, 1994), verapamil in refractory multiple myeloma
(Dalton et al, 1995) and verapamil in SCLC (Milroy, 1993) and
showed no statistically significant difference in response rates or
survival between the treatment and the placebo arms. Only a
smaller randomized trial using verapamil in advanced NSCLC
revealed a statistically significant difference in median survival in
the treatment arm (Millward et al, 1993).
Possible reasons to explain the finding of no beneficial effect in
the treatment arm may relate to a suboptimal dose or schedule of
MA or the fact that P-gp-mediated drug resistance is not the major
contributor ofMDR in this patient population. In the laboratory, the
ability to reverse MDR has been shown to be dose related with MA
(Fleming et al, 1992) and other modulators including verapamil
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(Bellamy et al, 1988) and cyclosporin A (Twentyman et al, 1987),
and this probably also applies to the clinical situation. In the clin-
ical situation, information can be extrapolated from trials using MA
as an appetite stimulant and promoter ofimproved quality oflife. A
recent published randomized trial prescribed MA at 800 mg per
day starting 3-5 days after chemotherapy for 3-4 weeks until the
next course of the planned four courses and then for a total of 2
years in advanced SCLC patients. Even with this higher dose and
prolonged course, no difference in response rates or survival was
seen compared with placebo (Rowland et al, 1996). Our dose was
chosen for potential efficacy while minimizing risk of thrombo-
embolic complications, but perhaps a higher dose would have led
to different results.
Timing the initiation of MA, or any drug, to block P-gp-medi-
ated resistance may also be pivotal. The precise time in the evolu-
tion of drug resistance when modulators of MDR would be most
efficacious is not known. It was our hypothesis that modulation of
P-gp-mediated resistance at the earliest possible time, with the
least number of MDR clones present, would produce the most
benefit, and therefore this trial was designed to use MA with first-
line therapy. Perhaps it would be better to modulate MDR in those
who relapse or have primary refractory disease. In vitro studies
have demonstrated that the degree of sensitization of MA
increases with increasing P-gp expression (Fleming et al, 1992),
and thus perhaps a threshold number of cells expressing P-gp or
a threshold amount of P-gp on each cell needs to exist for
maximal gain.
If the dose and scheduling of MA were adequate in this trial, it
would lead to the conclusion that no benefit was seen because P-
gp is not the major contributor of MDR in SCLC. Although it has
been reported that some drug-resistant SCLC cell lines and
xenografts have increased MDR1 gene expression, other studies
have not demonstrated MDR1 gene amplification, MDR1 mRNA
overexpression, expression of P-gp or reversal of the resistance
with known modulating agents in SCLC (Cole et al, 1980; Mirski
et al, 1987; Goldstein et al, 1989; Lai et al, 1989; Reeve et al,
1989). In addition, the degree of MDR1 expression has not been
shown to correlate with in vitro chemosensitivity of cell lines or
clinical response to therapy (Lai et al, 1989). These observations
indicate that there is more than one type of biochemical pathway
leading to MDR in SCLC. Some of these mechanisms of drug
resistance have been elucidated, such as multidrug resistance
protein expression (MRP) (Cole et al, 1992), qualitative and quan-
titative changes in topoisomerase II (De Jong et al, 1990) and
glutathione-S-transferase (Arvelo et al, 1990). Whether this is a
reflection of intrinsic properties of different cell types within the
cell line or whether a single cell possesses multiple mechanisms of
drug resistance is unknown.
A limitation of this clinial study is that P-gp levels were not
measured at presentation, progression or relapse. This gives no
objective evidence that the patient's tumours expressed P-gp
initially, that P-gp expression was altered with MA administration
or that expression changed with progression or relapse.
It was expected that the addition of MA would improve the
symptom profile, as it has been shown in previous trials to
improve subjective and objective nutritional status. The reasons
for no difference in symptom profiles between the two arms may
be that the symptom profile assessment instrument was not sensi-
tive enough to detect a small difference, that the dosing and
schedule of MA was not optimal or that MA does not improve
quality of life parameters significantly.
In summary, it could not be shown that the addition of MA, in
the dose and schedule used, to first-line cytotoxic therapy in SCLC
improves median overall survival, time to disease progression,
response rates or patient symptom profile.
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